Shashanka P Ashili from Eagan, MN, age 50

Resumes

Shashanka Ashili Ballwin, MO

view source

Work:

ARIZONA STATE UNIVERSITY
Tempe, AZ
2008 to 2012
Assistant Research Scientist / Postdoctoral Research Associate, Biosignatures Discovery Automation

Education:

UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE
Charlotte, NC
2003 to 2008
PhD in Science and Engineering WRIGHT STATE UNIVERSITY
Fairborn, OH
2000 to 2002
Electrical Engineering REGIONAL ENGINEERING COLLEGE
Warangal, Andhra Pradesh
1995 to 1999
BTech in Electronics and Communication Engineering

Us Patents

Device And Method For The Study Of Cell And Tissue Function
view source
US Patent:

20120231533, Sep 13, 2012
Filed:

Oct 28, 2009
Appl. No.:

13/126700
Inventors:

Mark R. Holl - Tempe AZ, US
Deirdre R. Meldrum - Phoenix AZ, US
A. Cody Youngbull - Tempe AZ, US
Haixin Zhu - Chandler AZ, US
Jeff Houkal - Tempe AZ, US
Yanqing Tian - Chandler AZ, US
Shashanka Ashili - Phoenix AZ, US
Laimonas Kelbauskas - Gilbert AZ, US
Roger Johnson - Phoenix AZ, US
Shih-hui Chao - Phoenix AZ, US
Peter Wiktor - Phoenix AZ, US
Alex Jen - Kenmore WA, US
Lloyd Burgess - Seattle WA, US
Sarah McQuaid - Seattle WA, US
Ai Brunner - Phoenix AZ, US
Peter Kahn - Phoenix AZ, US
International Classification:

C12M 1/34
US Classification:

4352879, 4352887
Abstract:

A chamber device for analyzing living cell(s). The chamber device includes a base and a lid that when reversibly pressed closed create a chamber. The base is configured with an optically transparent well to contain at least one cell. The lid has a breadth greater than the base and is configured to contain at least one sensor. The lid is further configured with a lip that when pressed between the lid and the base creates an impermeable seal. The base and the lid are configured so that, when closed and in use, the sensor remains spatially apart from the at least one cell.

Enhancement Of Mesenchymal Stem Cell Anti-Inflammatory And Regenerative Activity Using Mtor Inhibitors
view source
US Patent:

20210386789, Dec 16, 2021
Filed:

Jun 11, 2021
Appl. No.:

17/345885
Inventors:

- San Diego CA, US
Feng Lin - San Diego CA, US
Sandeep Pingle - San Diego CA, US
Shashanka Ashili - Rosemount MN, US
Assignee:

BRAIN CANCER RESEARCH INSTITUTE - San Diego CA
International Classification:

A61K 35/28
A61K 31/436
A61K 31/675
C12N 5/0775
Abstract:

The invention teaches the unexpected finding that treatment of mesenchymal stem cells with inhibitors of mammalian target of rapamycin (mTOR) lead to enhancement of regenerative and/or anti-inflammatory activity of said stem cells. In one embodiment, rapamycin treatment of mesenchymal stem cells (MSC) is associated with enhanced basal and stimulated production of therapeutic factors. In one embodiment other regenerative activities are enhanced by treatment with inhibitors of mTOR such as angiogenesis, neurogenesis, protection from apoptosis, and immune modulation.

Augmentation Of Cell Therapy Efficacy By Inhibition Of Complement Activation Pathways
view source
US Patent:

20210353685, Nov 18, 2021
Filed:

May 14, 2021
Appl. No.:

17/320890
Inventors:

- San Diego CA, US
Feng Lin - San Diego CA, US
Sandeep Pingle - San Diego CA, US
Shashanka Ashili - Rosemount MN, US
International Classification:

A61K 35/28
C07K 16/18
A61K 39/395
A61K 45/06
Abstract:

Disclosed are means, methods and compositions of matter useful for treatment of inflammatory and/or viral mediated disease through administration of cellular populations subsequent to modulation of complement pathway. In one embodiment, patients with COVID-19 who are eligible for stem cell therapy are pretreated with modulators of complement activity in order to reduce inflammation and to augment activity of said stem cell therapy. Activity of said stem cell therapy includes protection of pulmonary cells from dysfunction/death, stimulation of regenerative/trophic activities, reduction of inflammation, and induction of immune modulation.

Reduction Of Pulmonary Inflammation Using Therapeutic Gas Mixtures
view source
US Patent:

20210338713, Nov 4, 2021
Filed:

May 3, 2021
Appl. No.:

17/306719
Inventors:

- San Diego CA, US
Feng Lin - San Diego CA, US
Sandeep Pingle - San Diego CA, US
Shashanka Ashili - Rosemount MN, US
International Classification:

A61K 33/00
A61K 9/00
Abstract:

Disclosed are compositions of matter, protocols, and combination therapies useful for reduction of pulmonary inflammation associated with conditions such as acute respiratory distress syndrome (ARDS), ventilator induced inflammation, and infectious disease induced inflammation. In one embodiment the invention provides therapeutic gases which induce anti-apoptotic, anti-inflammatory, and immune modulatory properties in the pulmonary environment of a patient in need of therapy.

Tolerogenic Dendritic Cells For Treatment Of Acute Respiratory Distress Syndrome
view source
US Patent:

20210330705, Oct 28, 2021
Filed:

Apr 22, 2021
Appl. No.:

17/237475
Inventors:

- San Diego CA, US
Feng Lin - San Diego CA, US
Sandeep Pingle - San Diego CA, US
Shashanka Ashili - Rosemount MN, US
International Classification:

A61K 35/15
A61K 31/436
Abstract:

Disclosed are compositions of matter, cells, and therapeutic protocols useful for treatment of acute respiratory distress syndrome (ARDS). In some embodiments the invention teaches treatment of ARDS caused by viruses including COVID-19 through administration of an immature population of dendritic cells at a concentration and frequency to inhibit pulmonary inflammation, alveolar leakage, and loss of pulmonary function. In some embodiments immature dendritic cells are generated by culture of autologous and/or allogeneic monocytes with IL-4 and GM-CSF without a maturation step. In other embodiments, generation of immature dendritic cells is performed by administration on NF-kappa B inhibitors. In other embodiments dendritic cells are utilized in an immature form to stimulate generation of T regulatory cells.

Treatment Of Acute Respiratory Distress Syndrome By T Regulatory Cells
view source
US Patent:

20210308186, Oct 7, 2021
Filed:

Apr 7, 2021
Appl. No.:

17/224909
Inventors:

- San Diego CA, US
Feng Lin - San Diego CA, US
Sandeep Pingle - San Diego CA, US
Shashanka Ashili - Rosemount MN, US
International Classification:

A61K 35/28
C07K 14/535
C07K 14/47
C07K 14/495
C07K 14/55
Abstract:

Described are means, methods and compositions of matter for treatment of acute respiratory distress syndrome (ARDS) by enhancement of T regulatory (Treg) number and/or efficacy. In one embodiment of the invention, exogenous Tregs are administered. In another embodiment, enhanced endogenous Tregs are provided using methods including administration of low dose interleukin-2, administration of other cytokines, and administration of cells which stimulate Treg generation such as mesenchymal stem cells.

Tamper Resistant System For Creating Zones And Manipulating Computing Devices
view source
US Patent:

20170339270, Nov 23, 2017
Filed:

Nov 7, 2015
Appl. No.:

15/524125
Inventors:

Shashanka Ashili - Eagan MN, US
International Classification:

H04M 1/725
H04W 4/04
G06F 21/86
G06F 21/62
Abstract:

A system for selectively manipulating a mobile device when the mobile device is present within one or more defined zones within an area. The system comprises a control device transmitting a signal, with the signal having a decreasing signal strength as distance from the control device increases. The system additional comprises one or more profiles stored in a memory for determining the one or more defined zones based on one or more values, each value corresponding to a particular signal strength of the signal, and at least one software application executing on the mobile device. The application is configured for accessing the profiles from a memory and receiving, from the mobile device, an indication of the signal received at the mobile device and a signal strength of the received signal, and selectively manipulating the mobile device as a function of the signal strength and the one or more profiles.